CliffBio
small molecule

SYMTUZA

COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

Loss of exclusivityJuly 2038latest FDA-listed patent expiry
CompanyJANSSEN PRODUCTS LP

Drug detail

Brand nameSYMTUZA
Active ingredientCOBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Strength150MG;800MG;200MG;EQ 10MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2018
Marketing statusRX

Listed patents

PatentExpiresType
10786518July 2038use U-2978
10039718October 2032product
8754065August 2032substance, product
9296769August 2032substance, product
8148374September 2029substance, product
7700645December 2026substance, product

More from JANSSEN PRODUCTS LP

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

SYMTUZA patent cliff — loss of exclusivity July 2038 | CliffBio